文献速递炎症性肠病

炎症性肠病患者联合治疗的适宜性:一种方案仍不能适合所有患者

Appropriateness of Combination Therapy for Patients With Inflammatory Bowel Diseases: One Size Still Does Not Fit All.
PubMed 文献 · Clin Gastroenterol Hepatol · 2018-03-02

本文评述了抗肿瘤坏死因子(TNF)和α₄β₇整合素单药治疗在溃疡性结肠炎(UC)或克罗恩病(CD)中诱导和/或维持缓解的随机对照试验(RCT)证据,指出联合免疫调节剂(IM)治疗的额外获益数据不明确。在CD中,RCT数据混杂,系统综述和荟萃分析显示总体无获益、个别药物获益甚微或优于某些单药治疗但不优于其他单药;在UC中,RCT显示获益可能限于特定人群,而系统综述提示完全无获益。

要点

  • 抗TNF和α₄β₇整合素单药治疗在UC或CD中诱导和/或维持缓解有效。
  • 联合IM治疗是否带来额外获益,RCT数据不明确。
  • CD中联合治疗证据混杂,UC中获益可能限于特定人群或完全无获益。

核心结论

  • 联合免疫调节剂治疗是否优于单药治疗因疾病和人群而异,一种方案仍不能适合所有患者。

研究设计与样本

  • 本文为针对随机对照试验(RCT)及系统综述和荟萃分析证据的评述。

主要发现

  • 在CD中,RCT数据混杂,系统综述和荟萃分析显示总体无获益、个别药物获益甚微或优于某些单药治疗但不优于其他单药。
  • 对两种药物均未使用过的CD患者,硫唑嘌呤联合英夫利西单抗比任一单药更有效。
  • 联合治疗是否比英夫利西单抗单药更有效(对非初治患者)或比其他已批准生物制剂单药更有效(任何人群),仍未知。
  • 在UC中,RCT显示获益可能限于特定人群,而系统综述提示完全无获益。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Randomized controlled trials (RCTs) have demonstrated that therapies targeting tumor necrosis factor (TNF) and α₄β₇ integrin are effective when given as monotherapy in inducing and/or maintaining remission in patients with ulcerative colitis (UC) or Crohn's disease (CD), but data from RCTs are less clear on whether concomitant immunomodulator (IM) therapy confers additional benefit. In CD, RCT data are mixed,1,2 as are results of systematic reviews and meta-analyses, showing no benefit overall,3 minimal benefit with individual agents,4 and comparative benefit over some monotherapies but not others.5 For example, concomitant azathioprine with infliximab is more effective than either drug alone in patients with CD naive to both drugs,2 but whether combination therapy is more effective than monotherapy with infliximab in nonnaive patients, or with other approved biologic drugs in any population, remains unknown. In UC, RCTs have shown that the benefit may be limited to specific populations,6 whereas systematic reviews suggest no benefit at all.7.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Melmed GY, Kaplan GG, Sparrow MP, et al. Appropriateness of Combination Therapy for Patients With Inflammatory Bowel Diseases: One Size Still Does Not Fit All. Clin Gastroenterol Hepatol. 2018. PMID: 29505910. doi:10.1016/j.cgh.2018.02.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。